11 January: Eli Lilly announces positive top results from Phase II study of donanemab in Alzheimer’s disease

On 11 January, the pharmaceutical company Eli Lilly announced that its Phase II clinical trial evaluating donanemab in Alzheimer’s disease (AD) met its primary endpoint. Donanemab is an investigational antiamyloid therapy, targeting a modified form of beta amyloid called N3pG.

Read more »
Rate: 12345 (7) | Facebook Twitter
18 January: AE adds two new trials to its Clinical Trials Watch

We continue to develop and improve our Clinical Trials Watch, which provides up-to-date accessible information on phase II and III clinical trials for dementia/Alzheimer’s treatment/prevention, and currently recruiting in Europe. In January 2021, two new Phase II trials have been added.

Read more »
Rate: 12345 (0) | Facebook Twitter
25 January: Italy finally gets funding for its National Dementia Plan

Federazione Alzheimer Italia has been instrumental in securing funding for Italy's national dementia plan. While the Plan has been in place since 2014, it had no associated funding. Specific funding will allow the country to start transforming objectives into concrete actions to support people with dementia.

Read more »
Rate: 12345 (1) | Facebook Twitter
25 January: LETHE project holds virtual kick-off meeting

LETHE is a personalised prediction and intervention model for early detection and reduction of risk factors causing dementia, based on AI and distributed Machine Learning. It is a four-year project funded under Horizon 2020.

Read more »
Rate: 12345 (0) | Facebook Twitter
28 January: European Alzheimer’s Alliance members back call for dementia to be prioritised

Members of the European Alzheimer’s Alliance (EAA) have shown their support for the prioritisation of dementia at an EU level, following the publication of the Alzheimer Europe report, “Dementia as a European Priority – A Policy Overview”.

Read more »
Rate: 12345 (0) | Facebook Twitter
1 February: Neuronet releases Knowledge Base representing key information on 18 neurodegeneration research projects

On 1 February, the members of the Neuronet (Efficiently Networking European Neurodegeneration Research) programme announced the launch of a pan-European Knowledge Base which brings together key information about the 18 projects of the Innovative Medicines Initiative (IMI) neurodegeneration (ND) portfolio.

Read more »
Rate: 12345 (0) | Facebook Twitter